Gerold Nepom - Director, Benaroya Research Institute at Virginia Mason and Affiliate Professor of Immunology, University of Washington School of Medicine. http://www.airmid.com/GeroldNepom.html Airmid is a privately held pharmaceutical company based in Redwood City, California. Airmid is focused on developing its novel potassium ion channel blockers as safer and more effective medicines for a variety of autoimmune diseases that are inadequately treated by current therapies. http://www.airmid.com/index.html Autoimmune Disease is a family of disorders resulting from tissue damage caused by a malfunctioning immune system, affecting tens of millions of people worldwide. http://www.airmid.com/autoimmune-disease.html Multiple sclerosis is a disease caused by autoimmune damage to the central nervous system including the brain, which affects roughly two and a half million people worldwide. http://www.airmid.com/multiple-sclerosis.html Type 1 diabetes mellitus - Type 1 diabetes mellitus is a disease caused by autoimmune destruction of insulin-producing cells in the pancreas, resulting in high blood sugar and other metabolic abnormalities. http://www.airmid.com/type-1-diabetes-mellitus.html Kv1.3 Potassium Channel - A voltage-gated, delayed-rectifier potassium ion channel that regulates membrane potential and calcium signaling in human effector memory T cells. http://www.airmid.com/kv-potassium-channel.html PAP-1 is a small molecule Kv1.3 blocker that was developed through classical medicinal chemistry from the medicinal plant Ruta graveolens (= the common rue or the herb of grace). http://www.airmid.com/pap-1.html Shk : ShK-186, one novel synthetic analog, has a selectivity profile for the Kv1.3 potassium channel that is far greater than that of the naturally derived peptide. http://www.airmid.com/shk.html Effector Memory T cells - A highly mature population of immune T-cells shown to be responsible for the tissue damage which characterizes many autoimmune diseases. http://www.airmid.com/effector-memory-t-cells.html Airmid company overview. http://www.airmid.com/aboutus_overview.html Airmid Company background - Airmid is a privately held virtual pharmaceutical company based in Redwood City, California. http://www.airmid.com/background.html Airmid team - information of Board of Directors, Drug Development Committee, Clinical Advisory Board and Other Founders. http://www.airmid.com/theteam.html George Milijanich - CEO of Airmid. Dr. Miljanich was previously Senior Medical Director at Elan Pharmaceuticals and has over 18 years experience in pharmaceutical research, development, and commercialization. http://www.airmid.com/pe-george-Milijanich.html Marc Schneidman - Director and founder Airmid. Vice President of Biotechnology Value Fund (BVF) Partners LP. Mr. Schneidman is a portfolio management and investment researcher at BVF and has over 10 years experience in biotechnology investment. http://www.airmid.com/Marc-Scheidman.html George Chandy - Director and founder of Airmid. Professor, Physiology & Biophysics, Microbiology & Molecular Genetics, and Medicine, University of California, Irvine. http://www.airmid.com/KGeorgeChandy.html Michael Pennington - President and COO of Bachem Bioscience, Inc. Dr. Pennington possesses over 17 years experience in the chemistry, pharmacology, manufacturing, and sale of pharmaceutical peptides and small molecules. http://www.airmid.com/MichaelPennington.html Heike Wulff - Assistant Professor, Medical Pharmacology and Toxicology at the University of California, Davis. Dr. Wulff is the world's foremost authority on the pharmaceutical chemistry of PAP-1 and its derivatives. http://www.airmid.com/HeikeWulff.html George Shopp - Principal, Shopp Nonclinical Consulting LLC. Dr. Shopp has 22 years experience in the fields of toxicology, pharmacology, pharmacokinetics and drug development. http://www.airmid.com/GeorgeShopp.html Christine Beeton - Christine Beeton is an Assistant Researcher in the Department of Physiology and Biophysics at UC Irvine. http://www.airmid.com/ChristineBeeton.html Jan Wallace - Principal, Wallace Ranch Consulting. Dr. Wallace has over 20 years experience developing a broad range of small molecule pharmaceuticals and biologics. http://www.airmid.com/JanWallace.html Peter Calabresi - Associate Professor of Neurology, Director of the Multiple Sclerosis Center, and co-Director of the Division of Neuroimmunology and Neuro-infectious Diseases at Johns Hopkins University School of Medicine. http://www.airmid.com/PeterCalabresi.html Jerry McCullough - Professor of Dermatology, University of California Irvine School of Medicine. Dr. McCullough is an internationally recognized authority in basic and clinical dermatology. http://www.airmid.com/JerryMcCullough.html Michael Cahalan - Michael Cahalan is Professor of Physiology and Biophysics at UC Irvine and pioneered investigations of ion channels in cells of the immune system using electrophysiological and optical imaging methods. http://www.airmid.com/MichaelCahalan.html Raymond Norton - Dr. Norton is Professor at the University of Melbourne, Australia. His research focuses on the determination of polypeptide and protein structures by NMR spectroscopy and on structure-based molecular design. http://www.airmid.com/RaymondNorton.html George Gutman - Dr. Gutman is Professor of Microbiology and Molecular Genetics at the University of California Irvine. http://www.airmid.com/GeorgeGutman.html Katalin Kalman - Dr.Kalman earned a PhD in Genetics and Biochemistry from the Jozsef Attila University in Hungary. Dr.Kalman is an Assistant Researcher in the Department of Physiology and Biophysics at the University of California, Irvine. http://www.airmid.com/KatalinKalman.html Evan Gruber - Modtech Holdings Inc.; practicing accountant; member of the boards of directors of several public and private companies. http://www.airmid.com/EvanGruber.html Airmid company Target Portfolio. http://www.airmid.com/targetportfolio.html Unment Needs - The unmet need for autoimmune therapies is very large. http://www.airmid.com/targetportfolio_unment.html AIRMID's Novel Therapeutic Approach. http://www.airmid.com/targetportfolio_noveltherap.html AIRMID's Therapeutics - AIRMID's founders have succeeded in developing therapeutically promising Kv1.3 blockers even as several large pharmaceutical companies have failed. http://www.airmid.com/targetportfolio_therapeutics.html Airmid's Excellent Safety Profiles. http://www.airmid.com/targetportfolio_excellent.html Proof-of-concept AIRMID Technology. http://www.airmid.com/targetportfolio_proof.html Airmid's Key Publications. http://www.airmid.com/keypublications.html Airmid Press release. http://www.airmid.com/press.html Sitemap - links to all important pages of the site. http://www.airmid.com/sitemap.html